Antigermix and Hypernova Chronos Proven effective against HPV
Human papillomaviruses (HPV) are responsible for over 5% of human cancers worldwide. Nearly all cases of cervical cancer are the result of HPV infection, as well as a significant number of anogenital and oropharyngeal cancers. While HPV is commonly known to be transmitted by sexual contact, the public is unaware of the risk of HPV infection through non-sexual transmission [1]. Often the potential for non-sexual infection by HPV is ignored or dismissed by healthcare professionals.
As well as being transmitted sexually, HPV can be also passed from one person to another via ultrasound probes. This alarming reality is backed up by strong clinical evidence. That is why all precaution needs to be taken to ensure the high level disinfectant you have chosen for your ultrasound probes has been proven effective against HPV.
The evaluation of the Antigermix against HPV was conducted at Penn State College of Medicine and Penn State Cancer Institute under the leadership of Craig Meyers, Distinguished Professor of Microbiology and Immunology. This in vitro trial evaluated Antigermix efficacy against HPV 16 and HPV 18 – these two types are responsible for 95% of the cervical cancers and 7% of the cancers worldwide – and concludes that “No infectious virus remained after treatment in the Antigermix AS1 device (...) Antigermix AS1 is effective to kill HPV 16 and HPV 18 in a greater proportion than 4-log and can claim virucidal activity against HPV”.
As a consequence, Antigermix is the only HLD proven efficient against HPV both in laboratory and in real usage conditions as two former studies showed Antigermix to be efficient against HPV in clinical use. Moreover, it is the only system fast enough to not impair ultrasound usual workflow with a 90 seconds cycle time.